Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H PALMER

Showing results (991-1000 of 1,033) with videos related to

Pageof 104
Sort By:
Cold Spring Harbor Molecular Case Studies|June 17, 2018
Clinical response of the novel activating ALK-I1171T mutation in neuroblastoma to the ALK inhibitor ceritinibJikui Guan, Susanne Fransson, Joachim Tetteh Siaw, et al.
British Journal of Cancer|June 22, 2018
Circulating biomarkers during treatment in patients with advanced biliary tract cancer receiving cediranib in the UK ABC-03 trialAlison C Backen, Andre Lopes, Harpreet Wasan, et al.
Oncotarget|June 23, 2018
The Nrf2 inhibitor brusatol is a potent antitumour agent in an orthotopic mouse model of colorectal cancerJonathan P Evans, Boleslaw K Winiarski, Paul A Sutton, et al.
Oncotarget|February 19, 2019
Correction: The Nrf2 inhibitor brusatol is a potent antitumour agent in an orthotopic mouse model of colorectal cancerJonathan P Evans, Boleslaw K Winiarski, Paul A Sutton, et al.
The Lancet. Oncology|July 17, 2015
Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trialJuan W Valle, Harpreet Wasan, Andre Lopes, et al.
The EMBO Journal|January 7, 2021
ALK ligand ALKAL2 potentiates MYCN-driven neuroblastoma in the absence of ALK mutationMarcus Borenäs, Ganesh Umapathy, Wei-Yun Lai, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 5, 2023
Colonization With Antibiotic-Resistant Bacteria in a Hospital and Associated Communities in Guatemala: An Antibiotic Resistance in Communities and Hospitals (ARCH) StudyBrooke M Ramay, Carmen Castillo, Laura Grajeda, et al.
Plos One|February 3, 2017
Microbiome sharing between children, livestock and household surfaces in western KenyaEmily Mosites, Matt Sammons, Elkanah Otiang, et al.
Leukemia & Lymphoma|January 29, 2021
Haematological malignancy and nosocomial transmission are associated with an increased risk of death from COVID-19: results of a multi-center UK cohortTalvinder Bhogal, Umair T Khan, Rebecca Lee, et al.
Pediatrics|July 27, 2011
A randomized study of a monoclonal antibody (pagibaximab) to prevent staphylococcal sepsisLeonard E Weisman, Helen M Thackray, Robin H Steinhorn, et al.
Pageof 104

Showing results (991-1000 of 1,033) with videos related to

Sort By:
Pageof 104
Cold Spring Harbor Molecular Case Studies|June 17, 2018
Clinical response of the novel activating ALK-I1171T mutation in neuroblastoma to the ALK inhibitor ceritinibJikui Guan, Susanne Fransson, Joachim Tetteh Siaw, et al.
British Journal of Cancer|June 22, 2018
Circulating biomarkers during treatment in patients with advanced biliary tract cancer receiving cediranib in the UK ABC-03 trialAlison C Backen, Andre Lopes, Harpreet Wasan, et al.
Oncotarget|June 23, 2018
The Nrf2 inhibitor brusatol is a potent antitumour agent in an orthotopic mouse model of colorectal cancerJonathan P Evans, Boleslaw K Winiarski, Paul A Sutton, et al.
Oncotarget|February 19, 2019
Correction: The Nrf2 inhibitor brusatol is a potent antitumour agent in an orthotopic mouse model of colorectal cancerJonathan P Evans, Boleslaw K Winiarski, Paul A Sutton, et al.
The Lancet. Oncology|July 17, 2015
Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trialJuan W Valle, Harpreet Wasan, Andre Lopes, et al.
The EMBO Journal|January 7, 2021
ALK ligand ALKAL2 potentiates MYCN-driven neuroblastoma in the absence of ALK mutationMarcus Borenäs, Ganesh Umapathy, Wei-Yun Lai, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 5, 2023
Colonization With Antibiotic-Resistant Bacteria in a Hospital and Associated Communities in Guatemala: An Antibiotic Resistance in Communities and Hospitals (ARCH) StudyBrooke M Ramay, Carmen Castillo, Laura Grajeda, et al.
Plos One|February 3, 2017
Microbiome sharing between children, livestock and household surfaces in western KenyaEmily Mosites, Matt Sammons, Elkanah Otiang, et al.
Leukemia & Lymphoma|January 29, 2021
Haematological malignancy and nosocomial transmission are associated with an increased risk of death from COVID-19: results of a multi-center UK cohortTalvinder Bhogal, Umair T Khan, Rebecca Lee, et al.
Pediatrics|July 27, 2011
A randomized study of a monoclonal antibody (pagibaximab) to prevent staphylococcal sepsisLeonard E Weisman, Helen M Thackray, Robin H Steinhorn, et al.
Pageof 104